Precision medicine leaders gather in Beijing for first China-U.S. Precision Medicine Summit
Precision medicine is changing the way patients are being diagnosed and treated for illnesses, and Thermo Fisher is leading the charge in its advancement. In March, government, academic, and industry leaders from China and the U.S. came together to strengthen partnerships and collaborations at the first-ever China-U.S. Precision Medicine Summit. The event was co-hosted by CEO Roundtable on Cancer and the China Academy of Medical Sciences & Peking Union Medical College.
"China and the United States are leading the way in developing both the tools and the therapies to advance precision medicine, and Thermo Fisher is uniquely positioned to enable that advancement," said Mark Stevenson, chief operating officer, in his opening remarks. More than 450 attendees gathered for presentations and discussions on the most relevant topics in precision medicine today, including, advancements in diagnosis and treatment of cancer; new targeted therapies and technologies; the impact of digital science; and healthcare and government policy considerations to foster collaboration and accelerate progress.
Mark Stevenson underscored the importance of collaboration across borders and the broad impact that precision medicine is already demonstrating. "The application of precision medicine is far broader than just oncology. Precision medicine is helping the blind see, giving hope to kids with cystic fibrosis that they can live past their twenties, and ensuring the right dose of the best drug for an individual patient."
As a company, Thermo Fisher has made a significant commitment to advancing precision medicine. Last year, we opened a Precision Medicine Science Center in Guangzhou, China, and recently opened a second Precision Medicine Science Center in Cambridge, Massachusetts. Both centers will showcase Thermo Fisher’s innovative products, platforms, and services to support precision medicine.
"I left the meeting excited about the role Thermo Fisher can play as we deepen bilateral understanding of research and clinical applications in precision medicine," said Stevenson. "It moves us one step closer to ending diseases such as cancer for a healthier world."
Value of measuring health profiles over time: Andrew Kasarskis, Director, Icahn Institute for Genomics and Multiscale Biology
Enabling precision therapy for children with cancer: Dr. Timothy Triche, Co-Director, Center for Personalized Medicine (Pediatric Oncology), Children’s Hospital Los Angeles (CHLA)
For Research Use Only. Not for use in diagnostic procedures.